Similar articles

Abstract: In aged patients, acute kidney injury (AKI) is a common clinical complication after percutaneous coronary intervention (PCI), highlighting the need for timely and certain diagnosis of this disease. A single centre, nested case-control study was conducted, which assessed the usefulness of urinary liver-type fatty acid-binding protein (uL-FABP), neutrophil gelatinase-associated lipocalin (uNGAL), and kidney injury molecule-1 (uKIM-1) for early detection of AKI. One hundred and thirty-two patients at or over 60 years old undergoing PCI were included. Serum creatinine (SCr) was measured before PCI, 24 and 48 h after PCI; uL-FABP, uNGAL, and uKIM-1 were measured before PCI, 6, 24, and 48 h after PCI. We identified 16 AKI patients and selected 32 control patients matched by admission time (<1 week), age (±5 years), and gender. In the receiver operating characteristic (ROC) curve analysis, the areas under the curve (AUCs) for the relative measurements of uL-FABP, uNGAL, and uKIM-1 were 0.809, 0.867, and 0.512 at 6 h after PCI, and 0.888, 0.840, and 0.676 at 24 h after PCI, respectively. AUC for the combination of uL-FABP and uNGAL was 0.899 at 6 h after PCI, and 0.917 at 24 h after PCI. Thus, measurement of uL-FABP and uNGAL levels at 6 and 24 h after PCI may be useful in detecting AKI in aged patients. Measurement of uKIM-1 levels provides inferior predictive power for early diagnosis of AKI.

老年患者经皮冠状动脉介入术后急性肾损伤的早期诊断的研究

[1]Andò G, de Gregorio C, Morabito G, et al., 2014. Renal function-adjusted contrast volume redefines the baseline estimation of contrast-induced acute kidney injury risk in patients undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv, 7(4):465-472.

[2]Andò G, Cortese B, Frigoli E, et al., 2015. Acute kidney injury after percutaneous coronary intervention: rationale of the AKI-MATRIX (acute kidney injury-minimizing adverse hemorrhagic events by TRansradial access site and systemic implementation of angioX) sub-study. Catheter Cardiovasc Interv, 86(5):950-957.

[3]Dieterle F, Sistare F, Goodsaid F, et al., 2010. Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat Biotechnol, 28:455-462.

[4]James MT, Samuel SM, Manning MA, et al., 2013. Contrast-induced acute kidney injury and risk of adverse clinical outcomes after coronary angiography: a systematic review and meta-analysis. Circ Cardiovasc Interv, 6:37-43.

[5]Kamijo A, Sugaya T, Hikawa A, et al., 2004. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol, 165(4):1243-1255.

[6]Katagiri D, Doi K, Honda K, et al., 2012. Combination of two urinary biomarkers predicts acute kidney injury after adult cardiac surgery. Ann Thorac Surg, 93(2):577-583.

[7]Liebetrau C, Gaede L, Doerr O, et al., 2014. Neutrophil gelatinase-associated lipocalin (NGAL) for the early detection of contrast-induced nephropathy after percutaneous coronary intervention. Scand J Clin Lab Invest, 74(2):81-88.

[8]Luo Q, Zhou F, Dong H, et al., 2013. Implication of combined urinary biomarkers in early diagnosis of acute kidney injury following percutaneous coronary intervention. Clin Nephrol, 79:85-92.

[9]Manabe K, Kamihata H, Motohiro M, et al., 2012. Urinary liver-type fatty acid-binding protein level as a predictive biomarker of contrast-induced acute kidney injury. Eur J Clin Invest, 42(5):557-563.

[10]McCullough PA, Sandberg KR, 2003. Epidemiology of contrast-induced nephropathy. Rev Cardiovasc Med, 4(Suppl 5):S3-S9.

[11]Mishra J, Ma Q, Prada A, et al., 2003. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol, 14(10):2534-2543.

[12]Nash K, Hafeez A, Hou S, 2002. Hospital-acquired renal insufficiency. Am J Kidney Dis, 39(5):930-936.

[13]Parikh CR, Thiessen-Philbrook H, Garg AX, et al., 2013. Performance of kidney injury molecule-1 and liver fatty acid-binding protein and combined biomarkers of AKI after cardiac surgery. Clin J Am Soc Nephrol, 8(7):1079-1088.

[14]Reddan D, Laville M, Garovic VD, 2009. Contrast-induced nephropathy and its prevention: what do we really know from evidence-based findings? J Nephrol, 22(3):333-351.

[15]Schrezenmeier EV, Barasch J, Budde K, et al., 2017. Biomarkers in acute kidney injury—pathophysiological basis and clinical performance. Acta Physiol (Oxf), 219(3):554-574.

[16]Shao X, Tian L, Xu W, et al., 2014. Diagnostic value of urinary kidney injury molecule 1 for acute kidney injury: a meta-analysis. PLoS ONE, 9(1):e84131.

[17]Singer E, Markó L, Paragas N, et al., 2013. Neutrophil gelatinase-associated lipocalin: pathophysiology and clinical applications. Acta Physiol (Oxf), 207(4):663-672.

[18]Stacul F, van der Molen AJ, Reimer P, et al., 2011. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol, 21(12):2527-2541.

[19]Torregrosa I, Montoliu C, Urios A, et al., 2015. Urinary KIM-1, NGAL and L-FABP for the diagnosis of AKI in patients with acute coronary syndrome or heart failure undergoing coronary angiography. Heart Vessels, 30(6):703-711.

[20]van Timmeren MM, van den Heuvel MC, Bailly V, et al., 2007. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol, 212(2):209-217.

[21]Zhou F, Luo Q, Wang L, et al., 2016. Diagnostic value of neutrophil gelatinase-associated lipocalin for early diagnosis of cardiac surgery-associated acute kidney injury: a meta-analysis. Eur J Cardio-thorac Surg, 49(3):746-755.

[22]List of electronic supplementary materials

[23]Data S1 Materials, methods, and declarations